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Efficacy of perioperative chemotherapy with advanced non-small-
cell lung cancer
Kim, Sun-Young1 Son, Choon Hee2 Yoo, Jung-Sun3 Joung, Mi-Kyong1 
Lee, Yu-Jin1 Lee, Jeong Eun1 Park, Hee Sun1 Jung, Sung Soo1 Kim, 
Ju-Ock4 
1 Department of Internal Medicine, Chungnam National University 
Hospital and Cancer Research Institute, Dae-jeon, Korea 2 College 
of Medicine, Dong-A University Hospital, Busan, Korea 3 College of 
Medicine, Inha University Hospital, In-chon, Korea 4 Department of 
Internal Medicine, Chungnam National University Hospital and Cancer 
Research Institute, Dae-Jeon, Korea 
Background: In advanced non-small-cell lung cancer (NSCLC), the 
use of combined modality regimens, utilizing chemotherapy, surgery 
and radiotherapy produces modest improvements in median survival, 
but overall survival remains poor. We performed a retrospective study 
of combined modality regimens including prophylactic cranial ir-
radiation (PCI) to evaluated the efﬁcacy on the patients with locally 
advanced NSCLC.
Methods: 30 patients diagnosed as stage lllA - lllB NSCLC from Sep-
tember 2001 to January 2005, received combined modality regimens. 
All patients treated with 100 mg/m2 of cisplatin given for 3 cycles in 
combination with gemcitabine, docetaxel or paclitaxel neoadjuvant 
chemotherapy, followed by surgery, and then received cisplatin-based 
chemotherapy for 3 cycles of adjuvant chemotherapy. Chest radiothera-
py was left to the decision of investigator.
Results: 23 patients (76.7%) had stage lllA disease and 7 patients 
(23.3%) had stage lllB disease. 20 patients received postoperative chest 
radiotherapy and 12 patients received PCI. The median duration of 
follow-up was 23 (7-64) months. The median survival was 27 (9-64) 
months and disease-free survival was 20 (7-64) months. The objec-
tive response rate (2CR+25PR) were 90%. The 1-year overall survival 
rate was 80% and 2-year overall survival rate was 46.7%. Grade 3/4 he-
matologic toxicities adverse drug reactions (ADRs) of neoadjuvant che-
motherapy were neutropenia (n=2) and that of adjuvant chemotherapy 
were neutropenia (n=3) and thrombocytopenia (n=2). Non-hematologic 
grade 3/4 ADRs in adjuvant chemotherapy were nausea. 
Conclusions: This study demonstrated that perioperative chemotherapy 
was feasible and resulted in good response and overall survival. 
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ERCC1 Expression is one of prognostic factors in completely 
resected non small-cell lung cancer patients with an adjuvant 
platinum-based chemotherapy
Kondo, Kazuya Fujino, Haruhiko; Takizawa, Hiromitsu; Miyoshi, 
Takanori; Hirose, Yukiko; Nagao, Taeko; Nakagawa, Yasushi; Toba, 
Hiroaki; Yoshida, Mitsuteru; Kenzaki, Koichiro; Sakiyama, Shoji; 
Tangoku, Akira 
Department of Oncological and Regenerative Surgery, The University 
of Tokushima Graduate School, Tokushima, Japan
Background: Recent several reports demonstrated that CDDP-based 
adjuvant chemotherapy should be offered as standard care to patients 
after completely resected early stage (pathological stage IB to II) non-
small-cell lung cancer (NSCLC). The cytotoxic effect of the antican-
cer drug CDDP is principally attributable to the formation of bulky 
intrastrand platinum-DNA adducts. Removal of these adducts from 
genomic DNA is mediated by the nucleotide excision repair pathway, a 
critical element of which for this function is the ERCC1 gene. For ad-
vanced NSCLC (inoperable III-IV stage) with chemotherapy combined 
of cisplatin and gemcitabine, Lord, et al. demonstrated that median 
overall survival was signiﬁcantly longer in patients with low ERCC1 
expression tumors compared to patients with high expression tumors 
(61.6 vs. 20.4 weeks). In this study, we investigated whether ERCC1 
mRNA expression level is a predictive factor for survival in patients 
with completely resected NSCLC followed by CDDP-based adjuvant 
chemotherapy.
Material and Methods: Between February 1991 and December 2001, 
86 patients were operated on for NSCLC and received CDDP-based 
chemotherapy postoperatively at the Tokushima University Hospital. 
The clinical ﬁndings of the patient were shown in the following; male: 
female=47:11, mean age=63.2, adenocarcinoma: 33 squamous cell 
carcinoma: 21, stage I: 8, II: 9, III: 37, IV: 4, lobectomy: 47, regimen 
CDDP+VDS: 42, cycle 1:=34, 2:=21.
Only tumor cells were gotten from parafﬁn-embedded tumor specimens 
using laser-captured microdissection (PALM Microlaser Technologies). 
After RNA isolation, cDNA was prepared from each sample. Relative 
cDNA quantitation for ERCC1 and an internal reference gene (a-actin) 
was done using a ﬂuorescence based, real-time detection method (ABI 
PRISM 7700 Sequence Detection System; TaqMan; Applied Biosys-
tems). The rise of the a-actin signal after cycle 31 using the described 
conditions indicated an insufﬁcient amount of mRNA present for the 
subsequent ERCC1 quantitation.
Results: In 58 of parafﬁn-embedded specimen of 86 patients, ercc1 
mRNA expression could be measured. The mean ERCC1 expression, 
relative to the expression of the internal control housekeeping genea-
actin, was 1.29 (range, 0.17 to 3.76). There were no signiﬁcant associa-
tions between ERCC1 levels and any of the factors age (p=0.48), sex 
(p=0.437), histology histology (squamous cell carcinoma (mean: 1.49) 
vs. adenocarcinoma: (1.17), p=0.221), and tumor stage (I (1.64) and II 
(1.54) vs. III (1.19) and IV (0.96); p=0.153). However, there was a ten-
dency that ERCC1 levels was higher in squamous cell carcinoma and 
early stage tumor. A cut-off value 1.1 of ERCC1 level could segregate 
into poor and good prognosis subgroups. The 5 year survival rate of 
patients with high and low ERCC1 was 66.2% and 42.7%, respectively 
(p=0.0531). The patients with high ERCC1 level showed a favor prog-
nosis compared with those with low ERCC1 level.
Conclusion: Although the patients with low ERCC1 level showed a 
favor prognosis for advanced NSCLC (inoperable III-IV stage) with 
CDDP-based chemotherapy, The patients with high ERCC1 level 
showed a favor prognosis in completely resected NSCLC patients with 
an adjuvant CDDP-based chemotherapy.
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Anaemia as prognostic and predictive factor of non-small cell 
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Background: Anaemia is one of the most common symptoms of lung 
cancer. The incidence of anaemia depends on clinical stage, kind of 
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tumour type, treatment methods used. Clinically signiﬁcant symptoms 
are found in 20-60% cancer patients. Lung cancer anaemia, deﬁnited as 
haemoglobin level below 12 g/dl is seen in 25-60% of patients depend-
ing on clinical stage (I-IV).
Materials and Methods: Between August 1997 and July 2000 in 
The Maria Sklodowska-Curie Memorial Cancer Centre and Institute, 
Department of Lung Cancer and Thoracic Tumours, 112 patients were 
treated by chemoradiotherapy with stage IIIA and IIIB non-small lung 
cancer. Thirty eight of patients were analyzed (31 males and 7 females). 
Median age was 57.8 (range 38-72). Current and never smokers consti-
tuted respectively 71% and 29% of patients.
Karnofsky status performance deﬁned as 100, 90, 80 was found in re-
spectively 36.8%, 47.4% and 15.8% of patients. Clinical stage IIIA and 
IIIB were diagnosed in 14 (36.8%) and 24 (63.2%) patients. Sequential 
treatment was given to 24 (63.2%) and concurrent chemoradiation 
was used in 14 (36.8%) patients. All patients received cisplatin and 
vinorelbine. All patients were irradiated to 60 Gy, using 3D planning 
system (Helax).
Results: Thirty six patients (94.7%) received planned treatment (2 
cycles of chemotherapy and irradiation). Only two patients (5.3%) 
had not completed treatment. Seventy eight chemotherapy cycles was 
given. Cisplatin total dose was between 130 to 360 mg per patient 
(median: 271 mg). Median treatment time was 46.1 days (range: 10-74 
days). Overall survival time in all patients was 98.3 weeks (range: 23-
389 weeks). Median time to progression was 34.6 weeks (range: 1-130 
weeks). Median haemoglobin serum level before treatment was 12.7 
g/dl (range: 10.2-16.0 g/dl). Median haemoglobin serum level after 
treatment was 12.4 g/dl (range: 7.7-16.1 g/dl). Median haemoglobin 
serum level one month after the end of treatment was 12.8 g/dl (range: 
8.1-15.3 g/dl).
Summary: Anaemia could be found as independent prognostic factor 
for overall survival time of lung cancer patients treated by combined 
radiochemotheraphy and it also may offer a predictive value. The corre-
lation between serum haemoglobin level and survival will be presented.
Table. Clinical Characteristics
Parameter Pts %
Female 7 18.4
Male 31 81.6
Smokers 27 71
Never smokers 11 29
KPS 100 14 36.8
KPS 90 18 47.4
KPS 80 6 15.8
T2 8 21.1
T3 13 34.2
T4 17 44.7
N0 2 5.3
N1 1 2.6
N2 31 81.6
N3 4 10.5
CS IIIA 14 36.8
CS IIIB 24 63.2
RTCT concurrent 14 36.8
RTCT sequential 24 63.2
SCC 28 73.4
AC 1 2.6
NSCLC no subtype 9 23.7
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Background: NVB i.v. with CDDP has reported an optimal activity/
tolerance ratio when used in combination with radiotherapy (RT). The 
new oral formulation of NVB should be easier to use assuming a simi-
lar activity proﬁle. An international phase II trial with NVBo + CDDP 
as induction, followed by NVBo + CDDP + RT was implemented in 
order to evaluate the objective response (OR) following this combina-
tion by SWOG modiﬁed criteria and its safety (NCI-CTC v2).
Material and Methods: Patients (pts) between 18 and 70 years, with 
histologically proven untreated locally advanced inoperable stage 
IIIA/IIIB (supraclavicular lymph nodes and pleural effusion excluded) 
NSCLC, adequate bone marrow, hepatic and renal function, KPS ≥ 
80%, were treated with NVBo D1,8 60 mg/m2 cycle 1 and 80 mg/m2 
cycle 2 (if no grade 3-4 toxicity) and CDDP 80 mg/m2 every 3 weeks 
for 2 cycles as induction. Patients without progression received NVBo 
